What is the address of Société médicale Mathy de Rhumatologie?

The registered office of Société médicale Mathy de Rhumatologie is located at Rue du Prieuré, Godinne 2, 5530 Yvoir.

Is Société médicale Mathy de Rhumatologie still active?

Yes. According to the CBE (29 October 2026) Société médicale Mathy de Rhumatologie is active, legal situation “Normale toestand”, started on 24 June 2015.

Is Société médicale Mathy de Rhumatologie registered on Peppol?

Yes, Société médicale Mathy de Rhumatologie is registered on the Peppol network with ID 0208:0632697544.

What is the enterprise number of Société médicale Mathy de Rhumatologie?

The enterprise number of Société médicale Mathy de Rhumatologie is BE0632697544.

When was Société médicale Mathy de Rhumatologie founded?

Société médicale Mathy de Rhumatologie was founded on 24 June 2015.

Who are the directors of Société médicale Mathy de Rhumatologie?

According to the 2025 annual accounts, the directors of Société médicale Mathy de Rhumatologie are: Luc Mathy.

Is Société médicale Mathy de Rhumatologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 June 2015; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Société médicale Mathy de Rhumatologie make in 2025?

Société médicale Mathy de Rhumatologie posted a profit after taxes of € 105,493 in financial year 2025.

What is the revenue of Société médicale Mathy de Rhumatologie?

As a small company, Société médicale Mathy de Rhumatologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 147,303.

Société médicale Mathy de Rhumatologie (Private Limited)

Dossier Société médicale Mathy de Rhumatologie, printed on 29 October 2026 from databakkes.be/en/0632697544/societe-medicale-mathy-de-rhumatologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Société médicale Mathy de Rhumatologie from Yvoir, company number BE0632697544, closed financial year 2025 with a result of € 105,493 after tax. For that financial year Société médicale Mathy de Rhumatologie recorded a gross margin of € 147,303 and equity of € 779,453. Compared with financial year 2024, the result moved from € 118,160 to € 105,493. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.

What it is worth Growing

€ 779,453

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 105,493

▼ 11% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 100,088

▼ 45% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 105,265 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 21,285

▼ 1% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 2,884

▲ 1% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 178,797 Gross margin 2022: € 178,797 First fiscal year in the series	€ 151,069 Gross margin 2023: € 151,069 ▼ 16% vs 2022 (€ 178,797) Unfavourable step	€ 158,443 Gross margin 2024: € 158,443 ▲ 5% vs 2023 (€ 151,069) Favourable step	€ 147,303 Gross margin 2025: € 147,303 ▼ 7% vs 2024 (€ 158,443) Unfavourable step	▼ 7%
Profit after taxes	€ 119,698 Profit after taxes 2022: € 119,698 First fiscal year in the series	€ 103,977 Profit after taxes 2023: € 103,977 ▼ 13% vs 2022 (€ 119,698) Unfavourable step	€ 118,160 Profit after taxes 2024: € 118,160 ▲ 14% vs 2023 (€ 103,977) Favourable step	€ 105,493 Profit after taxes 2025: € 105,493 ▼ 11% vs 2024 (€ 118,160) Unfavourable step	▼ 11%
Equity	€ 953,088 Equity 2022: € 953,088 First fiscal year in the series	€ 739,065 Equity 2023: € 739,065 ▼ 22% vs 2022 (€ 953,088) Unfavourable step	€ 779,225 Equity 2024: € 779,225 ▲ 5% vs 2023 (€ 739,065) Favourable step	€ 779,453 Equity 2025: € 779,453 Unchanged (€ 779,225) Favourable step
Total debts	€ 17,126 Total debts 2022: € 17,126 First fiscal year in the series	€ 333,720 Total debts 2023: € 333,720 ▲ € 316,593 vs 2022 (€ 17,126) Unfavourable step	€ 83,749 Total debts 2024: € 83,749 ▼ 75% vs 2023 (€ 333,720) Favourable step	€ 111,818 Total debts 2025: € 111,818 ▲ 34% vs 2024 (€ 83,749) Unfavourable step	▲ 34%
Cash	€ 896,468 Cash 2022: € 896,468 First fiscal year in the series	€ 753,399 Cash 2023: € 753,399 ▼ 16% vs 2022 (€ 896,468) Unfavourable step	€ 182,674 Cash 2024: € 182,674 ▼ 76% vs 2023 (€ 753,399) Unfavourable step	€ 100,088 Cash 2025: € 100,088 ▼ 45% vs 2024 (€ 182,674) Unfavourable step	▼ 45%
Retained profit	€ 940,588 Retained profit 2022: € 940,588 First fiscal year in the series	€ 726,565 Retained profit 2023: € 726,565 ▼ 23% vs 2022 (€ 940,588) Unfavourable step	€ 766,725 Retained profit 2024: € 766,725 ▲ 6% vs 2023 (€ 726,565) Favourable step	€ 766,953 Retained profit 2025: € 766,953 Unchanged (€ 766,725) Favourable step
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 318,000 Dividend 2023: € 318,000 Unchanged (€ 0) Unchanged	€ 78,000 Dividend 2024: € 78,000 ▼ 75% vs 2023 (€ 318,000) Unchanged	€ 105,265 Dividend 2025: € 105,265 ▲ 35% vs 2024 (€ 78,000) Unchanged	▲ 35%
Balance sheet total	€ 970,215 Balance sheet total 2022: € 970,215 First fiscal year in the series	€ 1,072,785 Balance sheet total 2023: € 1,072,785 ▲ 11% vs 2022 (€ 970,215) Unchanged	€ 862,974 Balance sheet total 2024: € 862,974 ▼ 20% vs 2023 (€ 1,072,785) Unchanged	€ 891,272 Balance sheet total 2025: € 891,272 ▲ 3% vs 2024 (€ 862,974) Unchanged	▲ 3%

Key figures of Société médicale Mathy de Rhumatologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Société médicale Mathy de Rhumatologie?

What happened at Société médicale Mathy de Rhumatologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 29, 2026 New annual accounts for financial year 2025: profit of € 105,493 (▼ 11% vs 2024). Source: NBB ↗
2023 Luc Mathy became a director. NBB
Jun 24, 2015 Start of the company according to the CBE. KBO

In short

From € 119,698 profit in 2022 to € 105,493 profit in 2025.

Paid € 215,813 in corporate taxes since 2022.

Best year ever: 2022, with € 119,698 profit.

Paid out € 501,265 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Luc Mathy

Société médicale Mathy de Rhumatologie

Behind Société médicale Mathy de Rhumatologie is Luc Mathy.

Directors

According to the 2025 annual accounts

Luc Mathy

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Rue du Prieuré, Godinne 2

5530 Yvoir

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Maxillo

€ 683,673 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0632.697.544
VAT number: BE 0632.697.544
Registered office: Rue du Prieuré, Godinne 2, 5530 Yvoir
Names & denominations: Société médicale Mathy de Rhumatologie · SMMR
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 24 June 2015
Peppol: Active · Active since 25 Jun 2025

View on CBE Public ↗ Annual accounts (NBB) ↗